Systemic inflammation in gout and the impact of treat-to-target urate-lowering therapy
Authors' conclusion
Gout is characterized by distinct patterns of circulating inflammatory biomarkers and these appear to change over time with treat-to-target ULT to approximate controls.
Study context
- Population
- Individuals with gout from the STOP Gout study and non-gout controls from an institutional biobank
- Participants
- 278 vs 275
- Comparison
- Gout vs non-gout controls
- Goutn = 278
- Controlsn = 275reference
- Outcome
- Inflammatory score from standardized values of 20 inflammatory and cardiometabolic biomarkers (PCs associated with gout)
Methodological detailsvarimax-rotated principal component analysis (PCA), generalized estimating equation
- Varimax-rotated PCA
- Generalized estimating equation
Main finding
As reported in the abstract
Inflammatory score, gout vs controls · all three time points
- Five PCs statistically differed in gout at baseline vs controls after accounting for covariates
- Gout vs Controls: P < 0.001
Observational data: associations, not effects.
Further findings
Change in inflammatory score among gout cases on urate-lowering therapy (ULT) vs baseline · 24 and 48 weeks
- Decrease at 24 weeks vs baseline
- P = 0.01
- Decrease at 48 weeks vs baseline
- P < 0.001
Factors associated with change in inflammatory score
- Higher baseline score and time associated with reductions in inflammatory score
- Hypertension and higher baseline serum urate associated with increased inflammatory score
Original publication
Systemic inflammation in gout and the impact of treat-to-target urate-lowering therapy. Rheumatology (Oxford). Published 14 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →